These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36461940)

  • 41. Molnupiravir increases SARS-CoV-2 genome diversity and complexity: A case-control cohort study.
    Gruber CEM; Tucci FG; Giombini E; Mazzotta V; Spezia PG; Rueca M; Mastrorosa I; Fabeni L; Berno G; Butera O; Rosati S; Specchiarello E; Carletti F; Focosi D; Nicastri E; Girardi E; Antinori A; Maggi F
    J Med Virol; 2024 May; 96(5):e29642. PubMed ID: 38708812
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of the mutagenic effects of Molnupiravir and N4-hydroxycytidine in bacterial and mammalian cells by HiFi sequencing.
    Miranda JA; McKinzie PB; Dobrovolsky VN; Revollo JR
    Environ Mol Mutagen; 2022 Aug; 63(7):320-328. PubMed ID: 36181379
    [TBL] [Abstract][Full Text] [Related]  

  • 43. SARS-CoV-2 RdRp uses NDPs as a substrate and is able to incorporate NHC into RNA from diphosphate form molnupiravir.
    Wang M; Wu C; Liu N; Zhang F; Dong H; Wang S; Chen M; Jiang X; Zhang K; Gu L
    Int J Biol Macromol; 2023 Jan; 226():946-955. PubMed ID: 36528144
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of N4-hydroxycytidine incorporation into nucleic acids of SARS-CoV-2-infected host cells by direct measurement with liquid chromatography-mass spectrometry.
    Urbanowicz K; Opielka M; Stegmann KM; Dickmanns A; Dobbelstein M; Peters GJ; Smoleński RT
    Nucleosides Nucleotides Nucleic Acids; 2024 May; ():1-9. PubMed ID: 38741480
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Factors Influencing COVID-19 Risk: Insights From Molnupiravir Exposure-Response Modeling of Clinical Outcomes.
    Chawla A; Birger R; Wan H; Cao Y; Maas BM; Paschke A; De Anda C; Rizk ML; Stone JA
    Clin Pharmacol Ther; 2023 Jun; 113(6):1337-1345. PubMed ID: 37017631
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Buyer beware: molnupiravir may damage DNA.
    van Schalkwyk JM
    BMJ; 2021 Nov; 375():n2663. PubMed ID: 34737196
    [No Abstract]   [Full Text] [Related]  

  • 47. Virology and safety profile of Molnupiravir at three different doses for treatment of SARS-CoV-2: a systematic review and meta-analysis.
    Sukaina M; Shuja SH; Rehan ST; Ochani S; Sheryar M
    APMIS; 2024 Mar; 132(3):139-151. PubMed ID: 38288881
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A validated LC-MS/MS method for determination of antiviral prodrug molnupiravir in human plasma and its application for a pharmacokinetic modeling study in healthy Egyptian volunteers.
    Gouda AS; Marzouk HM; Rezk MR; Salem AM; Morsi MI; Nouman EG; Abdallah YM; Hassan AY; Abdel-Megied AM
    J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Aug; 1206():123363. PubMed ID: 35810537
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A computational comparative analysis of the binding mechanism of molnupiravir's active metabolite to RNA-dependent RNA polymerase of wild-type and Delta subvariant AY.4 of SARS-CoV-2.
    Celik I; Tallei TE
    J Cell Biochem; 2022 Apr; 123(4):807-818. PubMed ID: 35132671
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An Engineered Cytidine Deaminase for Biocatalytic Production of a Key Intermediate of the Covid-19 Antiviral Molnupiravir.
    Burke AJ; Birmingham WR; Zhuo Y; Thorpe TW; Zucoloto da Costa B; Crawshaw R; Rowles I; Finnigan JD; Young C; Holgate GM; Muldowney MP; Charnock SJ; Lovelock SL; Turner NJ; Green AP
    J Am Chem Soc; 2022 Mar; 144(9):3761-3765. PubMed ID: 35224970
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molnupiravir in COVID-19: A systematic review of literature.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2021; 15(6):102329. PubMed ID: 34742052
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molnupiravir: coding for catastrophe.
    Malone B; Campbell EA
    Nat Struct Mol Biol; 2021 Sep; 28(9):706-708. PubMed ID: 34518697
    [No Abstract]   [Full Text] [Related]  

  • 53. What impact can molnupiravir have on the treatment of SARS-CoV-2 infection?
    Kayali F; Leung MST; Wong W; Morgan KP; Harky A
    Expert Opin Pharmacother; 2022 Jun; 23(8):865-868. PubMed ID: 35341442
    [No Abstract]   [Full Text] [Related]  

  • 54. Molnupiravir for the treatment of COVID-19.
    Santani BG; LeBlanc BW; Thakare RP
    Drugs Today (Barc); 2022 Jul; 58(7):335-350. PubMed ID: 35851869
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro.
    Jonsdottir HR; Siegrist D; Julien T; Padey B; Bouveret M; Terrier O; Pizzorno A; Huang S; Samby K; Wells TNC; Boda B; Rosa-Calatrava M; Engler OB; Constant S
    Biomed Pharmacother; 2022 Jun; 150():113058. PubMed ID: 35658229
    [TBL] [Abstract][Full Text] [Related]  

  • 56. RdRp inhibitors and COVID-19: Is molnupiravir a good option?
    Hashemian SMR; Pourhanifeh MH; Hamblin MR; Shahrzad MK; Mirzaei H
    Biomed Pharmacother; 2022 Feb; 146():112517. PubMed ID: 34902743
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
    Sheahan TP; Sims AC; Zhou S; Graham RL; Pruijssers AJ; Agostini ML; Leist SR; Schäfer A; Dinnon KH; Stevens LJ; Chappell JD; Lu X; Hughes TM; George AS; Hill CS; Montgomery SA; Brown AJ; Bluemling GR; Natchus MG; Saindane M; Kolykhalov AA; Painter G; Harcourt J; Tamin A; Thornburg NJ; Swanstrom R; Denison MR; Baric RS
    Sci Transl Med; 2020 Apr; 12(541):. PubMed ID: 32253226
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of molnupiravir: A Danish nationwide drug utilization study.
    Ladebo L; Rasmussen L; Jensen PB; Lindahl M; Øvrehus A; Hallas J; Reilev M
    Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5700. PubMed ID: 37743261
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent.
    Lee CC; Hsieh CC; Ko WC
    Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827232
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.
    Sutanto ST; Sinto R; Pasaribu A; Shakinah S
    Acta Med Indones; 2022 Oct; 54(4):638-644. PubMed ID: 36624705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.